MASH

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver disease screening.

MASH cirrhosis carries high risks of death, decompensation, and liver cancer—especially with type 2 diabetes—while predictive tools remain limited.

Many MASH cirrhosis trials use histologic endpoints, but a new review finds limited standardization of these outcomes across studies.

Evidence suggests new therapies like GLP-1 receptor agonists, initially approved to treat obesity and diabetes, can also benefit patients with liver disease.

MASH can have a significant impact on patients’ quality of life, particularly if they have comorbidities or advanced fibrosis.

Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care.

The LPI/GPR55 axis is a key driver of MAFLD/MASH progression by promoting liver fat accumulation, inflammation, and fibrosis.

Resmetirom shows sustained quality-of-life gains in MASH and cirrhosis, easing abdominal symptoms and disease worry as liver fat drops.

In a cohort of veterans with steatotic liver disease, patients with metabolic- and alcohol-associated liver disease had the lowest incidence of cirrhosis.

MASLD and type 2 diabetes are closely interconnected conditions driven by shared metabolic dysfunction that together increase the risk of liver disease progression, cardiovascular complications, and mortality.

A review updates MASH diagnosis and prognosis guidelines, highlighting noninvasive scores, imaging, and emerging therapies, plus lifestyle strategies to improve outcomes.

New research highlights the effectiveness of targeted therapies for metabolic dysfunction–associated steatohepatitis (MASH), guiding treatment decisions and trial designs.

Semaglutide shows promise in improving liver health and metabolic outcomes in MASH, enhancing steatohepatitis resolution and cardiometabolic measures.

New research reveals gut microbiome changes in children with obesity signal liver disease progression, offering insights for early detection and intervention.

Researchers unveil a spatial multi-omics atlas revealing immune cell interactions and lipid metabolism's role in metabolic liver diseases, offering new therapeutic insights.

FDA granted breakthrough therapy designation to pemvidutide based on its potential in treating metabolic dysfunction–associated steatohepatitis (MASH).

A new analysis reveals effective therapies for reducing liver fat in metabolic dysfunction-associated steatohepatitis and highlights MRI-PDFF as a key measurement tool.

The algorithm could outperform existing noninvasive tools for identifying advanced fibrosis in MASH without producing indeterminate results.

Resmetirom improved MASH and fibrosis consistently across patients regardless of GLP-1 or SGLT2 inhibitor use, with outcomes further enhanced in those who achieved at least 5% weight loss.

A wide range of non-invasive tests reliably reflected semaglutide-related improvements in metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.

A national survey analysis suggests a link between higher Food Inflammation Index scores and metabolic liver disease.

Resmetirom showed comparable MASH resolution and fibrosis improvement in patients on GLP-1 RA or SGLT2i therapy and those on resmetirom alone.

Bariatric surgery halves mortality and reduces liver, heart, and kidney complications in steatotic liver disease vs nonsurgical care.